The Mount Sinai Hospital recently opened the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at 17 East 102nd Street, a facility created to provide comprehensive care in one location for pediatric and adult patients. Inflammatory Bowel Disease (IBD) is a general classification of conditions that cause inflammation of the intestines. An estimated 1.4 million people in the United States have Crohn’s disease and ulcerative colitis. Read more
For the first time in its 47-year history, the Crohn’s & Colitis Foundation of America has awarded all three of its 2014 annual scientific achievement awards to research and academic luminaries at the Mount Sinai Health System. Read more
More than one million Americans suffer from inflammatory bowel diseases (IBD), primarily Crohn’s disease and ulcerative colitis. Affecting people of any age, race or gender, IBD causes chronic inflammation of all or part of the digestive tract. Crohn’s can strike in any part of the system, while ulcerative colitis is only found in the large bowel. Patients’ symptoms vary widely, but the most common are diarrhea, abdominal pain or both.
As with many other digestive disorders, patients with IBD are constantly on a quest to find the right treatment regimen to relieve the symptoms that interfere with their everyday lives. This search for effective IBD treatments was one of the many topics my colleagues and I discussed during Digestive Disease Week® (DDW), the world’s largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.